Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis.

Borja Hernández-BreijoChamaida Plasencia-RodríguezVictoria Navarro-CompánAna Martínez-FeitoAndrea JochemsEva L KneepkensGerrit J WolbinkTheo RispensCristina DiegoDora Pascual-SalcedoAlejandro Balsa

Published in: Arthritis research & therapy (2019)

The use of concomitant csDMARDs with TNFi may increase the probability of achieving clinical response in overweight/obese axSpA patients. Further research studies including larger cohorts of patients need to be done to confirm it.

Keyphrases

end stage renal disease
chronic kidney disease
weight loss
peritoneal dialysis
prognostic factors
metabolic syndrome
rheumatoid arthritis
adipose tissue
type diabetes
systemic lupus erythematosus
weight gain